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Abstract. Malignant spinal cord compression (MSCC) is 
a serious complication of cancers. The present study aimed 
to establish a multidisciplinary treatment system for urgent 
magnetic resonance imaging (MRI) and referral to orthopedists 
in order to prevent neurological deficits caused by MSCC. In 
the present study, the extent to which this system achieved 
early diagnosis and treatment and prevented MSCC-caused 
neurological deficits was examined. The records from patients 
with neurological deficits caused by MSCC before (between 
April 2007 and March 2012; group A) and after (between 
April 2012 and March 2017; group B) the establishment of the 
multidisciplinary system at the Shikoku Cancer Center (Ehime, 
Japan) were retrospectively evaluated. The numbers of patients 
with neurological deficits were 38 and 7 in groups A and B, 
respectively. All patients received radiotherapy. The incidence 
of neurological deficits was 13.2 and 3.4% in groups A and B, 
respectively (P<0.001). The proportion of patients with improve-
ment in the severity of neurological deficits was 5.3 and 28.6% 
in groups A and B, respectively (P<0.001). The interval between 
physicians' recognition of a neurological deficit and MRI and 
the start of treatment, the number of cases, and the severity of 
neurological deficits were evaluated in groups A and B. The 
median interval between recognition of a neurological deficit 
by physicians and MRI was 3 and 0 days in groups A and B, 
respectively (P<0.001). The median interval between physicians' 
recognition of a neurological deficit and the start of treatment 
was 3 and 0 days in groups A and B, respectively (P<0.001). 
By using a multidisciplinary treatment system, the incidence 
and severity of neurological deficits following treatment were 
significantly improved. Therefore, the multidisciplinary treat-
ment system used in the present study may be useful for early 
diagnosis, treatment and prevention of MSCC in patients with 
bone metastases.
Introduction
Patients with bone metastases commonly present with spinal 
metastases, and 60‑70% of patients with advanced cancer 
develop spinal metastases during the progression of the 
disease (1,2). Spinal metastases are asymptomatic when their 
size and number are small; however, they gradually progress 
and frequently lead to skeletal-related events, including radiation 
therapy (RT) due to painful vertebral metastases, vertebral body 
fracture and malignant spinal cord compression (MSCC) (1). In 
patients without a neurological deficit, the pain from vertebral 
bone metastases can be controlled by RT in most cases (3). Our 
previous study reported that disappearance of pain and re-ossi-
fication were achieved at 3 months following RT in patients 
with painful vertebral bone metastases without paralysis (4). 
In addition, no patients presented with pain that was difficult 
to control with conventional radiotherapy or required surgery. 
Therefore, it was concluded that early diagnosis and treatment 
of bone metastases can lead to improved results (3,4).
MSCC is one of the most serious complications of 
cancer, and 2.5‑5% of patients with advanced cancer develop 
MSCC (1,2). MSCC can occur with all types of cancer; 
however, MSCC is most frequently observed in patients with 
breast, prostate or lung cancer (5,6).
In MSCC, the spinal cord is damaged by compression or 
vascular compromise due to tumor growth, which leads to 
neurological dysfunction (5,6). MSCC is an oncological emer-
gency since it causes motor weakness, sensory deficits, walk 
disturbance, and urinary and bowel dysfunction that markedly 
impair the quality of life (7-9).
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The importance of local control of bone metastases is 
increasing since patients with advanced cancer live longer 
due to recent advances in systemic therapies. Therefore, early 
diagnosis and treatment of MSCC, and a prophylactic approach 
for MSCC are crucial. however, several days may pass 
between the diagnosis and treatment of the neurological deficit 
(‘Doctor's Delay’), and the severity of the neurological deficit 
is often advanced at the time of referral to orthopedists and it 
is frequently difficult to improve the neurological deficit (8,9).
In most cases, back pain in the metastatic vertebral bone 
is the primary symptom preceding neurological dysfunc-
tion (5,10). Therefore, guidelines for bone metastases 
recommend that clinicians watch for early suspicious signs 
of MSCC and make a prompt diagnosis by spine magnetic 
resonance imaging (MRI) (5,10). According to the MSCC 
guidelines of the National Institute for health and Clinical 
Excellence in the united kingdom, spine MRI is recommended 
as soon as possible when symptoms of MSCC, including back 
pain and neurological deficit, appear in patients with a history 
of cancer (5).
doctors should communicate and share information 
regarding bone metastases in order to facilitate their treatment, 
since bone metastases occur in various types of cancer. It is 
crucial to establish a multidisciplinary treatment system for the 
management of bone metastases in hospitals (11-18). Recently, 
numerous institutions in Japan have organized cancer boards, 
including doctors, nurses and other paramedical staff, in order 
to focus on the management of bone metastases (19). however, 
the actual benefit of these cancer boards has not been clearly 
identified.
To the best of our knowledge, no study has reported a 
decreased incidence of neurological deficits due to spinal 
metastases when a multidisciplinary treatment system was 
implemented. Therefore, the present study investigated the 
change in the number of patients with neurological deficits 
before and after the establishment of a multidisciplinary treat-
ment system for bone metastases. furthermore, the differences 
in the time intervals to MRI and RT before and after the 
establishment of the multidisciplinary treatment system were 
examined.
Materials and methods
Patients and methods. The file records of 45 patients (24 male 
and 21 female; age, 30-82 years) who were followed-up in 
Shikoku Cancer Center (Matsuyama, Japan) for advanced 
cancer, presented with bone metastases and developed neuro-
logical deficits due to MSCC before (between April 2007 
and March 2012; group A) and after (between April 2012 
and March 2017; group B) the establishment of the multi-
disciplinary treatment system at the Shikoku Cancer Center 
were retrospectively evaluated. Patients were excluded if they 
had paralysis at their first presentation or the origin of the 
neurological deficit was the brain.
In 2012, a multidisciplinary treatment system for bone 
metastases was established at the Shikoku Cancer Center 
to prevent neurological deficits caused by vertebral bone 
metastases. Patients with bone metastases were identified 
by radiologists via regular computed tomography (CT). 
Contrast-enhanced CT was performed routinely.
The radiologists paid attention to destruction of the verte-
bral column cortex since this indicates the existence of MSCC 
(Fig. 1A‑D). When radiologists confirmed MSCC or severe 
vertebral body destruction (destruction of >1/3 of a vertebral 
body) during image interpretation, they described these find-
ings in their reports and wrote comments recommending 
referral of the patients to orthopedists for a consultation or 
to receive RT. Physicians could refer patients to orthopedists 
or radiotherapists after reading these comments.
The orthopedists met with the patients following referral 
by physicians. They evaluated the severity of the neurological 
deficit (motor function) according to the Frankel classifica-
tion (20). furthermore, they determined whether the origin of 
the neurological deficit was the brain, the spinal cord or other 
peripheral nerves. They also evaluated the spinal instability 
in order to decide whether conservative treatment (with or 
without orthosis) or surgery was required (3).
Additionally, physicians were advised to consider the exis-
tence of back pain in patients with vertebral bone metastases 
due to the associated-risk of developing paralysis. A rapid 
referral system was established to provide urgent access to 
MRI scanning, referral to orthopedists and administration of 
RT for the urgent management of neurological deficits caused 
by MSCC.
It was difficult to determine the precise number of patients 
with bone metastases. Therefore, the rate of patients with 
neurological deficits among those who received RT for verte-
bral metastases was investigated. The numbers of patients who 
received RT before and after the establishment of the system 
were 286 and 206, respectively (Table SI). The primary tumor 
sites of patients before the establishment of the system were 
lung (94 patients), breast (67), prostate (27), stomach (17) 
colorectum (12) and other (69). The primary tumor sites 
of patients after the establishment of the system were lung 
(65 patients), breast (46), prostate (34), colorectum (13), 
stomach (8) and other (40). The severity of neurological defi-
cits at the time of their recognition by physicians and at the 
time of treatment in groups A and B were evaluated using the 
Frankel classification (20).
The time intervals between the recognition of neuro-
logical deficits by physicians and MRI scanning and the start 
of treatment were also investigated. furthermore, the rate of 
referral to orthopedists for neurological deficits before treat-
ment and the use of bone-modifying agents (BMAs), such as 
denosumab or zoledronic acid were evaluated in groups A 
and B.
The present study was approved by the Ethical Review 
Board of Shikoku Cancer Center (Matsuyama, Japan) and 
conducted in accordance with the world Medical Association 
declaration of helsinki.
Statistical analysis. Categorical variables were analyzed using 
χ2 and fisher's exact tests. Continuous variables were analyzed 
using a Mann-whitney test. P<0.05 was considered to indicate 
a statistically significant difference. The kaplan-Meier method 
was used to estimate the overall survival rate in the two groups 
and the log-rank test was used to compare differences in the 
overall survival. All statistical analyses were performed 
with the statistical computing software R (R version 3.5.0; R 
Core Team).
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Results
MSCC prior to the establishment of the multidisciplinary 
treatment system. MSCC occurred in 38 patients in group A 
(Tables I and SII). The number of patients with neurological 
deficits in each of the 5 years was 8, 7, 6, 10 and 7, respec-
tively. The primary tumor sites were breast (12 patients), lung 
(8 patients), prostate (8 patients), colorectum (4 patients), 
stomach (4 patients), bile duct (1 patient) and multiple 
myeloma (1 patient). The affected locations in the spine were 
the cervical spine (1 patient), thoracic spine (30 patients) and 
lumbar spine (7 patients). The severity of the neurological 
deficit was Frankel A, B, C and D for 1, 1, 13 and 23 patients, 
respectively (Table SII). furthermore, one patient underwent 
surgery following RT, whereas the other patients received RT 
only.
MSCC after the establishment of the multidisciplinary 
treatment system. MSCC occurred in 7 patients in group B 
(Tables I and SII). The number of patients with neurological 
deficits in each of the five years was 0, 2, 1, 2 and 2, respec-
tively. The primary tumor sites were lung (4 patients) and 
breast (3 patients). The affected locations in the spine were the 
cervical spine (1 patient) and thoracic spine (6 patients). The 
severity of neurological deficit was frankel C and d for 3 and 
4 patients, respectively (Table SII). All patients from group B 
received RT.
Comparison between the number and severity of neurological 
deficits before and after the establishment of the multidisci-
plinary treatment system. Among the patients who received 
RT, the number of patients with neurological deficits was 
38/286 (13.2%) and 7/206 (3.4%) before and after the system 
was introduced, respectively (P<0.01). In patients with breast 
cancer, the rate of neurological deficits was higher in group A 
(12/67; 18%) compared with in group B (3/46; 6.5%); however, 
the difference was not identified to be significant (P=0.08). In 
patients with prostate cancer, the rate of neurological deficits 
was significantly higher in group A (8/27; 30%) compared 
with group B (0/34; 0%; P<0.01). In patients with cancer of 
the digestive organs, the rate of neurological deficits was 
significantly higher in group A (9/63; 14%) compared with 
group B (0/34; 0%; P=0.02). In patients with lung cancer, the 
rate of neurological deficits was higher in group A (8/97; 8.2%) 
compared with group B (4/65; 6.2%), although the difference 
was not identified to be significant (P=0.62) (Table SI).
In group A, the severity of neurological deficits was 
frankel A, B, C and d for 1, 1, 13 and 23 patients, respec-
tively, at the time of their recognition by physicians (fig. 2; 
Table SII). In 10/38 patients (26%), the severity of neurological 
deficit was worse at the time of treatment. Following treat-
ment, improvement in the severity of neurological deficit 
was achieved for 2 patients (5.3%) with Frankel D, but not in 
patients with frankel A, B or C. In patients with breast cancer, 
figure 1. Malignant spinal cord compression. (A and B) destruction of 
the cortex of the spinal cord column observed by computed tomography. 
(C and d) Malignant spinal cord compression observed by magnetic 
resonance imaging.
Table I. Characteristics of patients with bone metastases 
included in this study.
 Group A,  Group B,
Characteristic n (n=38) n (n=7)
Primary cancer site  
  Breast 12 3
  Lung 8 4
  Prostate 8 0
  Colorectal 4 0
  Stomach 4 0
  Others 2 0
Radiation site  
  Cervical spine 1 1
  Thoracic spine 30 6
  Lumbar spine 7 0
Severity of neurological  
deficit (Frankel classification)
  A 1 0
  B 1 0
  C 13 3
  d 23 4
Figure 2. Severity of neurological deficit at the time of recognition by physi-
cians, at treatment and after treatment in all patients before the establishment 
of the system. Improvement in the severity of neurological deficit could be 
attained in 2 patients (5.3%) after treatment compared with during treatment.
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the severity of neurological deficit was Frankel C and D for 
4 and 8 patients, respectively, at the time of recognition by 
physicians. In 3/12 patients (25%), the severity of neuro-
logical deficit was worse at the time of treatment. After 
treatment, no patient attained improvement in the severity 
of neurological deficit (Fig. 3). In patients with lung cancer, 
the severity of neurological deficit was Frankel C and D in 
1 and 7 patients, respectively, at the time of recognition by 
physicians. In 3/8 patients (38%), the severity of neurological 
deficit was worse at the time of treatment. Improvement in the 
severity of neurological deficit after treatment was attained in 
1 patient (12.5%) with Frankel D (Fig. 3).
In group B, the severity of neurological deficit was 
frankel C and d in 3 and 4 patients, respectively, at the time 
of recognition by physicians. No severe neurological defi-
cits (frankel A and B) and no deterioration of neurological 
deficits were observed at the time of treatment. After treat-
ment, improvement in the severity of neurological deficit 
was achieved by 2 patients (28.6%; Fig. 4). In patients 
with breast cancer, the severity of neurological deficit was 
frankel C and d in 1 and 2 patients, respectively, at the time of 
recognition by physicians. Improvement of neurological defi-
cits was attained in 2 patients after treatment (66.7%; Fig. 5). 
In patients with lung cancer, the severity of neurological deficit 
was frankel C and d in 2 patients each at the time of recogni-
tion by physicians. No patient achieved improvement in the 
severity of neurological deficits after treatment (Fig. 5).
The rate of patients with improvement in the severity of 
neurological deficit after treatment was significantly increased 
in all patients (group A, 5.3%; group B, 28.5%; P<0.001) and 
in patients with breast cancer (group A, 0%; group B, 66.7%; 
P<0.01), but not in patients with lung cancer (group A, 12.5%; 
group B, 0%; P=0.46) following the establishment of the 
system.
MRI scanning. The interval between the recognition of neuro-
logical deficits by physicians and MRI scanning was 0-23 days 
(median, 3 days) in group A (fig. 6, Table SII). MRI was not 
performed in 2 patients. The interval between the recogni-
tion of neurological deficits by physicians and MRI scanning 
was 0 days in 7 patients, 1-3 days in 13 patients, 4-7 days in 
8 patients and >7 days in 8 patients. The interval between the 
recognition of neurological deficits by physicians and MRI 
scanning was 0-1 days (median, 0 days) in group B. MRI was 
performed on the same day as the recognition of neurological 
Figure 3. Severity of neurological deficit at the time of recognition by physicians, at treatment and after treatment in patients with breast and lung cancer prior 
to the establishment of the system. In patients with breast cancer, no patient experienced improvement in the severity of neurological deficit after treatment. 
In patients with lung cancer, improvement in the severity of neurological deficit was attained in 1 patient (12.5%) prior to the establishment of the treatment 
system.
figure 4. Severity of neurological deficit at the time of recognition by 
physicians, at treatment and after the treatment in all patients after the estab-
lishment of the system. Improvement in the severity of neurological deficit 
was attained in 2 patients (28.6%) after treatment.
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deficits by physicians in 5 patients (71%) in group B. The 
interval between the recognition of neurological deficits by 
physicians and MRI scanning was significantly decreased 
after the establishment of the system (P<0.01; Table SI).
Treatment initiation. The interval between the recognition of 
neurological deficits by physicians and the start of treatment 
was 0-24 days (median, 3 days) in group A (Table SII). The 
interval between the recognition of neurological deficits by 
physicians and the start of treatment was 0 days in 5 patients, 
1-3 days in 17 patients, 4-7 days in 7 patients, and >7 days in 
9 patients (Table SII). The interval between the recognition of 
neurological deficits by physicians and the start of treatment 
was 0-1 days (median, 0 days) in group B (Table SII). Treatment 
was provided on the same day in all but 2 patients in group B. 
The interval between the recognition of neurological deficits 
by physicians and treatment was significantly decreased after 
the establishment of the system (P<0.01) (Table SII).
Referral to orthopedists. The rates of referral to orthopedists 
before treatment in groups A and B were 17/38 (45%) and 
7/7 (100%), respectively (P<0.01) (Table SII). The use of BMAs 
before the recognition of neurological deficits by physicians 
was 15/38 (39%) and 7/7 (100%) in groups A and B, respec-
tively (P<0.01) (Table SII). BMAs were administered at the 
time of diagnosis of bone metastases to all patients in group B.
Overall survival rates. At the last follow-up, 37/38 patients 
and 5/7 patients had died in groups A and B, respectively. The 
overall survival rates were 24 and 43% in groups A and B, 
respectively, at 6 months following RT with no significant 
difference identified (P=0.36; Fig. 7).
Discussion
The present study reported a significant improvement in the 
rate of neurological deficit cases when using a multidisci-
plinary treatment system for patients with bone metastases. 
Figure 5. Severity of neurological deficit at the time of recognition by physicians, at treatment and after treatment in patients with breast and lung cancer after 
the establishment of the system. In patients with breast cancer, improvement in the severity of neurological deficit was attained in 2 patients (66.7%) after the 
establishment of the system. In patients with lung cancer, no patient attained improvement in the severity of neurological deficit after treatment.
Figure 6. Time intervals between the recognition of neurological deficits by 
physicians, MRI scanning and treatment. The time intervals were signifi-
cantly decreased after the establishment of the treatment system of bone 
metastases (P<0.01).
figure 7. Overall survival of groups A and B estimated by the kaplan-Meier 
method, with no significant difference being observed (P=0.36).
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furthermore, the rate of patients with improvement in the 
severity of neurological deficit after treatment was improved 
after the establishment of the system.
An innovative treatment approach, including inten-
sity-modulated RT, vertebroplasty and minimally invasive 
surgery, has been developed (21). however, improvement of 
the neurological deficit is difficult once it occurs. Therefore, 
early diagnosis, treatment and prevention of MSCC are crucial 
in order to minimize treatment delay. In numerous cases, a 
neurological deficit does not occur suddenly, and back pain 
appears as a prodromal symptom for several weeks prior. 
Therefore, several guidelines for bone metastases recom-
mend that clinicians watch for this early sign of MSCC and 
provide an emergency diagnosis by using spine MRI (5,10). 
furthermore, the occurrence of MSCC should be considered 
when back pain appears in a patient with spinal metastases 
(so‑called ‘Red Flag̓), and emergency imaging, including 
CT or MRI, should be performed. when imaging cannot 
be performed immediately, the most recent imaging should 
be reviewed, and the presence of vertebral body collapse or 
asymptomatic MSCC should be confirmed. If treatment is 
initiated before a neurological deficit fully develops, it can be 
prevented in certain patients (preventable paralysis).
In the present study, the incidence of paralysis decreased 
following the establishment of the system. The rate of patients 
with neurological deficit and the rate of patients with improve-
ment in the severity of neurological deficit after treatment 
were significantly improved. In addition, among patients who 
received RT, the rate of patients with neurological deficit was 
38/286 (13.2%) and 7/206 (3.4%) before and after the estab-
lishment of the system, respectively, and this difference was 
identified to be significant. Although the rate of patients with 
neurological deficit was lower in all types of cancer, there 
was no significant difference observed between patients with 
breast and lung cancer.
Numerous patients presented with severe levels of neurolog-
ical deficit (Frankel A and B), and the severity of neurological 
deficit was worse at the time of treatment in 26% of patients 
before the establishment of the system. however, no severe 
level of neurological deficit and no deterioration of the neuro-
logical deficit were seen at the time of treatment after the 
establishment of the system.
The rate of patients with improvement in the severity of 
neurological deficit was 5.3 and 28.5% before and after the 
establishment of the system, respectively, which was signifi-
cantly different. urgent treatment with the system could lead 
to the prevention of the deterioration of the neurological deficit 
at the time of treatment and improvement of the neurological 
deficit.
The rate of patients with improvement in the severity of 
neurological deficit after treatment was significantly improved 
in patients with breast cancer, but not in patients with lung 
cancer, after the establishment of the system. This can be 
explained by the difference in the sensitivity to RT between 
patients with breast and lung cancer. Since breast cancer is 
more sensitive to RT (4), early treatment may lead to an 
improvement in the severity of neurological deficits.
It has been hypothesized that the increased awareness of 
back pain as a sign of MSCC and subsequent earlier referral 
to orthopedists could lead to the early diagnosis and treatment 
of MSCC. Additionally, the system depends on the capacity of 
radiologists to identify patients with vertebral body collapse 
who may require a potential prophylactic approach to prevent 
neurological deficit.
Previous studies have demonstrated that specific systems 
developed for earlier diagnosis and treatment can decrease 
treatment delays, which can lead to improved neurological 
outcomes of patients (11,18). Savage et al (11) reported the 
establishment of a rapid referral system designed to provide 
urgent access to MRI scanning and urgent referral to oncology 
specialists for the management of MSCC. key steps in the 
management of patients with suspicion of MSCC would 
include the capacity of physicians to directly connect with 
the oncology specialist in a tertiary center in order to provide 
access to urgent MRI scanning for patients. furthermore, 
physicians can provide an alert card to the patients with 
high risk of MSCC in order to encourage self-referral to the 
hospital when back pain, which is a potential symptom of 
MSCC, occurs. By using this approach, it has been reported 
that the rate of patients with major impairment decreased 
from 80 to 62% (11). Allan et al (18) reported a similar system 
for improving the time to diagnosis via a hotline by which 
physicians can directly connect with the oncology specialist 
in a tertiary center for patients with suspicion of MSCC and 
in urgent need for MRI scanning. using this approach, it has 
been reported that the time to MRI is shortened, and that 
the proportion of patients who are unable to walk at MRI 
decreases from 46 to 23% (18). These results suggest that the 
establishment of such a system is effective in daily clinical 
practice and that it can improve the time to referral.
furthermore, the present study reported a significant 
decrease in the time from the recognition of a neurological 
deficit by physicians to MRI scanning and treatment after the 
establishment of the treatment system for bone metastases. 
Approximately 40% of patients underwent MRI at >3 days 
following recognition of a neurological deficit by physicians, 
and in 26% of the patients, the severity of the neurological 
deficit was worse at the time of the treatment before the 
system was implemented. The rate of referral to orthopedists 
before treatment was only 45%. Conversely, all patients 
were referred to orthopedists, 71% of patients underwent 
MRI and RT on the same day, and the remaining 29% of 
patients underwent MRI and RT the day after the recognition 
of neurological deficit by physicians after the system was 
implemented.
The use of BMAs was also increased following the estab-
lishment of the system. Although the use of BMAs before the 
recognition of a neurological deficit by physicians was only 
39% in patients before the establishment of the system, they 
were administered at the time of diagnosis of bone metastases 
in all patients after the establishment of the system. This could 
be due to the increased efforts of physicians to treat patients 
with bone metastases.
A novel multidisciplinary treatment system is required to 
establish an effective and intensive diagnosis and treatment 
system for patients with bone metastases (19). hirai et al (17) 
demonstrated that early diagnosis through surveillance of 
bone metastases in patients with hepatocellular carcinoma 
can prevent fractures and paralysis, which can lead to an 
improved quality of life. Recently, cancer boards, including 
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teams of doctors specialized in orthopedy, oncology, palliative 
care, radiotherapy and radiology, nurses, physical therapists, 
occupational therapists and medical social workers, focusing 
on the management of bone metastases were organized in a 
number of institutions in Japan (19). In certain institutions, 
radiologists review all imaging studies of patients with bone 
metastases and can, thus, identify patients that may require 
a prophylactic approach to prevent paralysis (18). with this 
system, a common understanding of the importance of 
managing bone metastases is established among all members 
of the cancer board.
Although the multidisciplinary treatment system is effec-
tive for the management of bone metastases, this system 
presents some limitations. With this system, it can be difficult 
to identify patients with imminent development of MSCC 
in a timely manner. for example, in certain patients with 
osteoblastic bone metastases and extravertebral metastases, 
it can be hard for the radiologist to identify MSCC by routine 
CT alone. furthermore, physicians can occasionally overlook 
signs of MSCC, including back pain, motor dysfunction 
and sensory disturbance if they are not severe. In addition, 
patients do not always mention the back pain to physicians or 
do not come to the hospital when lower leg weakness is not 
severe. There is currently no system in The Shikoku Cancer 
Center (Matsuyama, Japan) that could be used to inform or 
educate patients about back pain as an early warning sign of 
MSCC, and alert them to go to hospital earlier. Therefore, 
neurological deficits cannot be prevented in some patients. 
The rate of early diagnosis and prevention of potential 
neurological deficits could be improved if patients with 
bone metastases had been informed about the importance of 
contacting physicians when complaining of back pain, espe-
cially when the pain is accompanied by neurological signs. 
Since MSCC occurs in only a small percentage of patients 
with bone metastases, it may be reasonable to select patients 
at high risk for education.
Another limitation of the system is the variable background 
of patients with bone metastases. Since patients presented with 
various types of primary tumor, metastatic sites, systemic 
therapies and general status at the time of the neurological 
deficit caused by MSCC, the individual prognoses were 
different. These factors could be responsible for the absence of 
a significant difference in the overall survival rates before and 
after the establishment of the system presented in the present 
study. however, these limitations are common in the study of 
bone metastases.
In conclusion, the present study demonstrated that the 
times between the recognition of a neurological deficit 
by physicians to MRI scanning and the treatment were 
significantly decreased after the establishment of the multi-
disciplinary treatment system for bone metastases. In addition, 
no deterioration of neurological deficits was observed at the 
time of treatment after the establishment of the multidisci-
plinary treatment system. furthermore, the rate of patients 
with improvement in the severity of neurological deficits after 
treatment was significantly increased. The establishment of 
a multidisciplinary treatment system for patients with bone 
metastases may therefore be useful for the early diagnosis 
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